A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa
Latest Information Update: 12 May 2025
At a glance
- Drugs Laruparetigene zovaparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Acronyms DAWN
- Sponsors Beacon Therapeutics
Most Recent Events
- 06 May 2025 Results presented in the Beacon Therapeutics Media Release.
- 06 May 2025 According to Beacon Therapeutics media release, company presented 6-month interim safety and efficacy results from at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held May 4-8, 2025 in Salt Lake City.
- 24 Apr 2025 According to Beacon Therapeutics media release, 6-month interim safety and efficacy results from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting